JP2023067056A - Hypogastric fat reducer - Google Patents

Abstract

To provide a fat reducer for a new use of removing the fat highly distributed in a region below a navel in the hypogastric region.SOLUTION: Bofu-tsusho-san extract, dai-saiko-to extract and/or boi-ogi-to extract is useful as an active ingredient of a hypogastric fat reducer.SELECTED DRAWING: None

Description

There is an application for the application of Article 30, Paragraph 2 of the Patent Law ▲1 ▼ Sales stores: Kyorindo Pharmacy (Shizuoka Yamazaki store, Shizuoka Oshika store, Fujieda Tanuma store, Fujieda Kiyosato store, Hogawa store, Niitsu store, Nishikaizuka store, Takaoka Higashi store , Shizuoka Otsubo store, Kasai store, Shitoro store, Kamijima station square store, Senagawa store, Uchino store, Wada store, P-One Plaza Tenno store, Kakegawa Kachoen-mae store, Fukuroi Asahicho store, Kamiokada store, Johoku store, Shizuoka Chiyoda store, Yaizu Yosoji store, Nazuka store, Himekaido store, Wago store) Sales start date: July 10, 2021 (2) Website address: https://lohaco. Yahoo. co. jp/https://lohaco. Yahoo. co. jp/search? p=%E3%83%93%E3%82%B9%E3%83%A9%E3%83%83%E3%83%88%E9%98%B2%E9%A2%A8%E9%80%9A %E8%81%96%E6%95%A3 Website publication date: July 28, 2021

TECHNICAL FIELD The present invention relates to a lower abdominal fat reducing agent.

In today's world of plentiful food, people are more likely to accumulate fat in their bodies, partly because of the convenience of living. The distribution of fat on the body is not uniform due to unspecified factors such as individual differences in bone structure, posture, and internal organ positions. The way fat is distributed on the abdomen is particularly diverse. Even in the area corresponding to the "lower abdomen", the distribution of fat thickness varies greatly depending on the person. Also in Non-Patent Document 1, as a result of specifically verifying the distribution state of the sebum thickness value, what ratio the sebum thickness of each part of the body adheres with an increase in the body fat percentage, especially abdominal sebum Thickness values show greater variability than any other measurement site.

Ethnic Health 62(2), 65-74, 1996-03-31

For modern people who want to reduce fat, taking a fat-reducing agent is easy and not difficult to continue, so it is easy to accept. However, until now, there have been no examples of fat-reducing agents that have been studied with a focus on reducing fat that is highly distributed in a specific region of the abdomen. No fat-reducing agent is yet known that shows higher efficacy for people with a highly distributed body type than for people without such a body type.

Accordingly, an object of the present invention is to provide a fat-reducing agent that can be used for a new purpose of reducing fat that is highly distributed in the region below the navel, even in the abdominal region.

The inventors of the present invention have found that Bofutsushosan extract, Daisaikoto extract, and Boukito extract are highly effective in reducing fat highly distributed in the region below the navel. The present invention has been completed through further studies based on this finding.

That is, the present invention provides inventions in the following aspects.
Section 1. A lower abdominal fat reducing agent containing a Bofutsushosan extract, a Daisaikoto extract and/or a Boukito extract.
Section 2. Item 1. The agent for reducing abdominal fat according to Item 1, which is applied to post-menopausal women.
Item 3. Item 3. The lower abdominal fat reducing agent according to Item 1 or 2, which is applied to women aged 55 or over.
Section 4. Applies to people with a ratio of lower to upper waist circumference of 1.1 or more,
Item 4. The agent for reducing abdominal fat according to any one of Items 1 to 3, wherein the upper abdominal circumference is the waist circumference at the navel level, and the lower abdominal circumference is the waist circumference at a position 50 mm below the navel level.
Item 5. Item 5. The agent for reducing abdominal fat according to any one of Items 1 to 4, which is applied to a person with a lower abdominal circumference of 100 cm or more.

INDUSTRIAL APPLICABILITY According to the present invention, a fat-reducing agent is provided for a new application of reducing fat highly distributed in the region below the navel.

Fig. 1 shows fat reduction effects of bofutsushosan (BTS), daisaikoto (DST), or bookito (BOT) on women with a protruding lower abdomen type body type. Fig. 1 shows fat reduction effect of Bofutsushosan (BTS), Daisaikoto (DST) or Boukito (BOT) on women with a slim figure. Fig. 1 shows the effect of Bofutsushosan (BTS), Daisaikoto (DST), or Boukito (BOT) on lower abdominal fat reduction in women with a protruding lower abdomen type body type. Fig. 1 shows the effect of Bofutsushosan (BTS), Daisaikoto (DST), or Boukito (BOT) on reducing abdominal fat in women with a slim figure. Figure 1 shows fat reduction effects of Bofutsushosan (BTS), Daisaikoto (DST) or Boukito (BOT) for women aged 55 and over. Figure 1 shows the effect of Bofutsushosan (BTS), Daisaikoto (DST) or Boukito (BOT) on reducing fat in women aged 40-54. Fig. 1 shows the effect of Bofutsushosan (BTS), Daisaikoto (DST), or Boukito (BOT) on reducing abdominal fat in women aged 55 and over. Fig. 1 shows the effect of Bofutsushosan (BTS), Daisaikoto (DST) or Boukito (BOT) on reducing abdominal fat in women aged 40 to 54. 1 shows the effect of Bofutsushosan (BTS), Daisaikoto (DST), or Boukito (BOT) on reducing abdominal fat in menopausal model mice. 1 shows the effect of Bofutsushosan (BTS), Daisaikoto (DST), or Boukito (BOT) on reducing epigastric fat in climacteric model mice. 1 shows the effect of Bofutsushosan (BTS), Daisaikoto (DST), or Boukito (BOT) on lower abdominal fat reduction in normal model mice. 1 shows the effect of Bofutsushosan (BTS), Daisaikoto (DST), or Boukito (BOT) on reducing epigastric fat in normal model mice.

The lower abdominal fat-reducing agent of the present invention is characterized by containing Bofutsushosan extract, Daisaikoto extract and/or Boukito extract as active ingredients.

As the active ingredient Bofutsushosan, a Chinese medicine prescription described in "New General Kampo Prescription Guide" (supervised by Yukihiro Goda and Takashi Hakamzuka, edited by the Japan Kampo Herbal Medicines Association, published by Jiho Co., Ltd.) is preferable. Mixed herbal medicines consisting of Peony, Cnidium, Sanshishi, Forsythia, Mentha, Ginger, Limonium, Ephedra, Ephedra, Rhubarb, Boshou, Byakujutsu, Platycodon, Scutellaria root, Glycyrrhiza, Gypsum, and Casseki. Depending on the letter, some of the above-mentioned crude drugs do not contain byakujutsu (for example, "Experience Kampo Prescription Quantity Collection", edited by Keisetsu Otsuka and Michiaki Yakazu, published by Ido no Nihonsha), and some do not contain scutellaria root (for example, " Zoku Kampo All About” edited by Osaka Yomiuri Shimbun, published by Naniwa Publishing). In addition, depending on the prescription of Bofutsushosan, some contain Hamaboufu instead of Bofu, and some contain Sojutsu instead of Byakujutsu.

In addition, the amount of each herbal medicine constituting Bofutsushosan is as follows: 1.2 parts by weight of Angelica keiskei, 1.2 parts by weight of Peony, 1.2 parts by weight of Senkyu, 1.2 parts by weight of Sanshishi and 1.2 parts by weight of Forsythia. , Peppermint 1.2 parts by weight, Ginger 0.3 to 1.2 parts by weight, Keigai 1.2 parts by weight, Ephedra 1.2 parts by weight, Ephedra 1.2 parts by weight, Rheum 1.5 parts by weight, Boshou 1 .5 to 3.0 parts by weight, 2.0 parts by weight of banyan tree, 2.0 parts by weight of Bellflower, 2.0 parts by weight of Scutellaria root, 2.0 parts by weight of licorice, 2 to 3 parts by weight of gypsum, 3 to 5 parts by weight of casseki is mentioned.

As Daisaikoto, the Kampo prescription described in the “New OTC Kampo Prescription Guide” (supervised by Yukihiro Goda and Takashi Hakamzuka, edited by the Japan Kampo Medicines Association, published by Jiho Co., Ltd.) is preferable. , pheasant, peony, ginger, taisoul, and rhubarb. In addition, Daisaikoto contains mixed crude drugs ( Kampo prescription) is included.

In addition, the amount of each herbal medicine constituting Daisaikoto is 3 to 12 parts by weight, preferably 4 to 9 parts by weight, of Saiko; 2 to 8 parts by weight, preferably 2.5 to 6 parts by weight of Hange; 1.5 to 6 parts by weight, preferably 2 to 4.5 parts by weight; 1 to 4 parts by weight, preferably 1.5 to 3 parts by weight, peony; 0.5 to 2 parts by weight, preferably 1 to 1.5 parts by weight of ginger; 1.5 to 6 parts by weight, preferably 2 to 4.5 parts by weight of rhubarb; .5 to 2 parts by weight, preferably 1 to 1.5 parts by weight.

For Boukito, the Kampo formulations listed in the ``New OTC Kampo Prescription Guide'' (supervised by Yukihiro Goda and Takashi Hakamzuka, edited by the Japan Kampo Herbal Medicines Association, published by Jiho Co., Ltd.) are preferable. , jutsu (byakujutsu and/or sojutsu), ginger, taiso, and licorice. In addition, as stipulated in the "Basic Policy for Handling Kampo Preparations" stipulated by the Kampo Crude Drug Research Committee, Bogiobukito contains mixtures described in letters related to Kampo medicines that are currently in frequent use. Herbal medicines (Chinese medicine prescriptions) are included.

In addition, the amount of each crude drug that constitutes Bogioto is 4 to 5 parts by weight of Bowie, 5 parts by weight of Astragalus japonicum, 3 parts by weight of Jutsu, 1 to 1.5 parts by weight of Ginger, and 3 to 4 parts by weight of Taiso. , and 1.5 to 2 parts by weight of licorice.

Bofutsushosan extract, Daisaikoto extract, and Boukito in the present invention are each obtained by extracting the above-described mixed herbal medicines, and concentrating the obtained extract as necessary to obtain an extract solution. It may be obtained as an extract powder by drying the extract liquid.

In the production of the Bofutsushosan extract, the Daisaikoto extract, and the Boukito extract, the extraction solvent used in the extraction treatment is not particularly limited, but examples thereof include water and hydrous ethanol. Also, the drying treatment is not particularly limited, and a known method such as a spray drying method, or adding an appropriate adsorbent (such as silicic anhydride, starch, etc.) to a soft extract with an increased concentration of the extract liquid. and a method of using it as an adsorption powder.

As the Bofutsushosan extract, Daisaikoto extract, and Boukito extract used in the present invention, the extract prepared by the method described above may be used, or commercially available products may be used. good. For example, Bofutsushosan dried extract A, Bofutsushosan dried extract AM, Bofutsushosan dried extract E, Bofutsushosan dried extract EM ” (both manufactured by Nippon Powder Co., Ltd.), “Bofutsuseisan Dried Extract-C”, “Bofutsuseisan Dried Extract-F” (both manufactured by Alps Pharmaceutical Industry Co., Ltd.), etc. known and commercially available. As the Daisaikoto extract powder, Daisaikoto dry extract AM, Daisaikoto dry extract SN, and Daisaikoto dry extract powder (all manufactured by Nippon Powder Co., Ltd.), and Daisaikoto dry extract F and Daisaiko Hot water dried extract-F (all manufactured by Alps Yakuhin Kogyo Co., Ltd.) and the like are known as commercial products, and can be obtained commercially. The extract powder of Boukito includes Boukito dry extract A and Boukito dry extract AZ (both manufactured by Nihon Powder Co., Ltd.), and Boukito extract powder and Boukito. Potato Dried Extract-F (both manufactured by Alps Yakuhin Kogyo Co., Ltd.) and the like are known as commercial products, and can be obtained commercially.

In the agent for reducing belly fat of the present invention, the content of the active ingredient is not particularly limited as long as the effect of the present invention is exhibited, but it is usually 5 to 80% by weight, preferably 5 to 80% by weight, in terms of the amount of dry herbal extract powder as the active ingredient. is 10 to 70% by weight, more preferably 20 to 60% by weight, and still more preferably 30 to 50% by weight. In the present invention, the term "converted amount of dried herb extract powder" refers to the amount of dried herb extract itself when using dried herb extract powder, and the residue obtained by removing the solvent when liquid extract of herb is used. It is the amount converted to quantity. In addition, when the dry herbal extract powder contains an additive such as an adsorbent added at the time of production, the amount does not include the additive.

Other Ingredients The agent for reducing belly fat of the present invention may, if necessary, contain other pharmacological ingredients in addition to the active ingredients described above. The types of such pharmacological ingredients are not particularly limited, but for example, antacids, stomachic agents, digestive agents, antiflatulents, antispasmodics, mucous membrane repair agents, anti-inflammatory agents, astringents, antiemetics, antitussives, expectorants, and antiphlogistic agents. Enzymatic agents, sedative hypnotics, antihistamines, caffeines, cardiotonic diuretics, antibacterial agents, vasoconstrictors, vasodilators, local anesthetics, crude drugs, crude drug extract powders, vitamins, menthols and the like. These pharmacological ingredients may be used singly or in combination of two or more. In addition, the content of these pharmacological ingredients may be appropriately set from known ones according to the type of the pharmacological ingredient to be used.

The lower abdominal fat-reducing agent of the present invention may contain pharmaceutically acceptable bases, additives, etc., as necessary, in order to prepare a desired dosage form. Examples of such bases and additives include excipients, binders, disintegrants, lubricants, tonicity agents, plasticizers, dispersants, emulsifiers, solubilizers, wetting agents, stabilizers, agents, suspending agents, adhesives, coating agents, brightening agents, water, oils and fats, waxes, hydrocarbons, fatty acids, higher alcohols, esters, water-soluble polymers, surfactants, metal soaps , lower alcohols, polyhydric alcohols, pH adjusters, buffers, antioxidants, UV inhibitors, preservatives, corrigents, fragrances, powders, thickeners, pigments, chelating agents and the like. These bases and additives may be used singly or in combination of two or more. Moreover, the contents of these bases and additives may be appropriately set from known ones according to the types of additive components to be used, dosage forms, and the like.

Dosage form The dosage form of the lower abdominal fat-reducing agent of the present invention is not particularly limited, and may be tablets, granules, powders, pills, capsules, films, liquids (drinks), and the like. Among these dosage forms, tablets, granules, and films are preferred from the viewpoint of ease of administration. These dosage forms can be prepared using pharmaceutically acceptable base materials and additives, and the types and blending amounts of the base materials and additives are also known in the field of formulation technology.

Application The agent for reducing belly fat of the present invention is used for the purpose of reducing the fat present 50 mm below the level of the navel among the fat distributed in the abdomen (meaning the front part of the trunk of the lower half of the body). . In other words, the “belly fat” in the present invention means fat present at a position 50 mm below the level of the navel. Supplementally, the “lower abdominal fat” in the present invention is distinguished from waist fat (which means fat usually present 30 mm above the navel level) among fats present in the abdomen, and further, Among the fat present below the waist level, it is distinguished from the abdominal fat (meaning the fat present at the navel level).

In the present invention, a reduction in "lower abdominal fat" can be confirmed by a reduction in the length of the lower abdominal circumference (meaning the waist circumference at a position 50 mm below the level of the navel).

The agent for reducing belly fat of the present invention is excellent in the effect of reducing belly fat at a position 50 mm below the navel level. Therefore, the lower abdominal fat-reducing agent of the present invention is preferably applied to a person with a body type in which fat is more highly distributed at a position 50 mm below the navel level than in other parts of the abdomen; Preferably, in the abdominal region, it is suitably applied to a person with a body type in which fat is distributed higher than the navel level at a position 50 mm below the navel level; A person whose ratio of lower abdominal circumference (waist circumference at a position 50 mm below navel height) to waist circumference at the waist position, or general abdominal circumference, is 1.1 or more, preferably 1.15. This is applicable to those who have a large protrusion of the lower abdominal fat region as described above. Although the upper limit of the range of the ratio is not particularly limited, it is, for example, 1.3 or less, preferably 1.25 or less.

Moreover, the lower abdominal fat reducing agent of the present invention is applied to a person whose lower abdominal circumference is, for example, 95 cm or more, preferably 100 cm or more. Although the upper limit of the waist circumference range is not particularly limited, it is, for example, 110 cm or less, preferably 105 cm or less.

In addition, the lower abdominal fat-reducing agent of the present invention is preferably applied to post-menopausal women (specifically, women aged 45 and over), and more preferably applied to women aged 55 and over.

Dosage/Usage The lower abdominal fat-reducing agent of the present invention is administered orally. The dosage of the lower abdominal fat-reducing agent of the present invention is appropriately set according to the amount of lower abdominal fat to be reduced, age, etc. For example, the daily intake is calculated in terms of the dried extract powder of the herbal extract. , 400 to 10,000 mg, preferably 1,300 to 6,000 mg. When the herbal extract is Bofutsushosan, 3,000 to 4,000 mg is particularly preferable. When the extract is Bogito extract, 3000 to 3500 mg is particularly preferable. The dosing timing is not particularly limited, and may be before, after or between meals, preferably before or between meals.

EXAMPLES The present invention will be specifically described below by way of examples, but the present invention is not limited to these examples.

Preparation of extract powder (1) Bofutsushosan (BTS) extract powder As crude drugs, 1.67 parts by weight of Bellflower, 1.67 byakujutsu, 1.67 parts by weight of licorice, 1.67 of Scutellaria root, 1.67 parts of gypsum 67, Rhubarb 1.25, Angelica 1.0, Peony 1.0, Cnidium 1.0, Sanshishi 1.0, Forsythia 1.0, Mentha 1.0, Limestone 1.0, Bohu 1.0, Ephedra 1.0 0, Ginger 0.33, Casseki 2.5, and Bosho 1.25. After chopping, extract with 20 times the weight of water at about 100 ° C. for 1 hour, centrifuge and extract. The extract was concentrated under reduced pressure and dried using a spray dryer to obtain Bofutsushosan extract powder. Drying with a spray dryer was performed by dropping the extract into an atomizer rotating at 10000 rpm and supplying hot air at 150°C.

(2) Daisaikoto (DST) extract powder As crude drugs, ginger 0.6 (parts by weight, the same applies hereinafter), taisou 1.8, psycho 3.6, peony 1.8, pheasant 1.2, hange 2 .4, 1.8 scutellaria root and 0.6 rhubarb, minced, extracted with 20 times the weight of water at about 100°C for 1 hour, centrifuged to obtain an extract, and reduced pressure. and dried using a spray dryer to obtain Daisaikoto extract powder. Drying with a spray dryer was performed by dropping the extract into an atomizer rotating at 10000 rpm and supplying hot air at 150°C.

(3) Bōgito (BOT) extract powder As crude drugs, ginger 1 (parts by weight, the same shall apply hereinafter), Ginger 3, Bowie 5, Byakujutsu 3, Astragalus 5, Glycyrrhiza 1.5 are used. After chopping, extract with 20 times the weight of water at about 100 ° C. for 1 hour, centrifuge to obtain an extract, concentrate under reduced pressure and dry using a spray dryer, Bogioto extract got the end Drying with a spray dryer was performed by dropping the extract into an atomizer rotating at 10000 rpm and supplying hot air at 150°C.

Test example 1
Before taking the drug, measure the lower abdominal circumference (the waist circumference at 50 mm below the navel level) and the upper abdominal circumference (the waist circumference at the navel level) for women aged 45 years or older, and adjust the ratio accordingly. Then, they were divided into a group with a protruding lower abdomen type and a group with a narrow body type. For the protruding type, the ratio of the lower abdominal circumference to the upper abdominal circumference was 1.1 or more, and the actual ratio was 1.15 to 1.25. The size of the body was less than 1.1, and the actual ratio was between 0.9 and 1.05.

The abdomen protruding type group and the short body type group were divided into a BTS-administered group, a DST-administered group, and a BOT-administered group, respectively. Bofutsushosan extract: 2.5 g, Daisaikoto extract: 2.4 g, and Boukito extract: 3.2 g per day, in 3 divided doses before or between meals. let me During the test period, no special exercise load was applied and no dietary restrictions were applied.

Before administration and 12 weeks after the start of administration, the whole body was photographed by X-ray CT, and the results of calculating the areas of visceral fat and subcutaneous fat are shown in FIG. The measurement results of lower abdominal circumference (waist circumference at a position 50 mm below navel level) before taking and 12 weeks after the start of taking are shown in FIG.

As is clear from the comparison of FIGS. 1 and 2, the abdominally protruding type group and the hump type group had the same total fat mass, but the amount of fat reduction was more pronounced in the abdominally protruding type group. In addition, as is clear from the comparison of FIGS. 3 and 4, it was confirmed that the lower abdominal circumference reduction effect tended to be more pronounced in the lower abdominal protruding group. 1 to 4, each of the Kampo extracts of BTS, DST, and BOT has a high effect of reducing lower abdominal fat, and furthermore, lower abdominal fat is particularly high in people with a protruding lower abdominal type. It was demonstrated that a reduction effect is exhibited.

Test example 2
Before the start of administration, a group of women aged 45 to 54 (15 people) and a group of women aged 55 to 67 (15 people) were targeted, and each group was further divided into a BTS-administered group, a DST-administered group, They were divided into BOT administration groups. Bofutsushosan extract: 3.1 g, Daisaikoto extract: 2.4 g, Boukito extract: 3.2 g per day, divided into 3 doses per day before or between meals let me During the test period, no special exercise load was applied and no dietary restrictions were applied.

Before taking the drug and 12 weeks after the start of taking the drug, the whole body was photographed by X-ray CT, and the results of calculating the area of visceral fat and subcutaneous fat are shown in Figure 5 (ages 55 and older) and Figure 6 (ages 45 to 54). show. In addition, before taking and 12 weeks after the start of taking, the measurement results of lower abdominal circumference (waist circumference at 50 mm below navel level) are shown in Figure 7 (ages 55 and over) and Figure 8 (ages 45-54). show.

As is clear from the comparison of FIGS. 5 and 6, although the 55-year-old group and the 45-54-year-old group had the same total fat mass, the amount of BTS, DST, and BOT Kampo extracts was The amount of fat reduction by administration was more remarkable in the 55-year-old or older group. In addition, as is clear from the comparison of FIGS. 7 and 8, it was confirmed that the effect of reducing the lower abdominal circumference by administering each of the herbal extracts BTS, DST, and BOT tended to become more pronounced in the 55-year-old and older group. 5 to 8, each of the Kampo extracts of BTS, DST, and BOT is highly effective in reducing lower abdominal fat, and is particularly effective in reducing lower abdominal fat for women aged 55 and over. was demonstrated to be played.

Test example 3
A climacteric model mouse was prepared by ovariectomizing female C57BL/6J mice at the age of 6 weeks and providing a recovery period of 1 week. In the test, ovariectomized mice were administered a high-fat diet (HFD32, Clea Japan, Inc.) containing 2% by weight of BTS, DST, and BOT (BTS-administered group, DST-administered group, BOT-administered group). ), and a group (non-administration (CONT) group) to which only a high-fat diet was administered was provided, and after 8 weeks of breeding, X-ray CT imaging was performed.

On the other hand, for normal mice, as in the climacteric mouse model, groups (BTS-administered group, DST-administered group, BOT-administered group) were administered with a high-fat diet containing 2% by weight of BTS, DST, and BOT, respectively. A group to which only high-fat diet was administered (non-administration group) was provided, and after 8 weeks of breeding, X-ray CT imaging was performed.

CT image of the middle position between the abdomen start position and the abdomen end position in the region recognized as the abdomen in the CT scan in the direction from the head to the tail of the mouse (that is, the region from the abdomen start position to the abdomen end position) The sum of the visceral fat and subcutaneous fat derived from is derived as the "upper abdominal fat area", and from the CT image at the 1/3 position from the intermediate position of the 3 equal parts between the intermediate position and the abdominal end position The total area of the derived visceral fat and subcutaneous fat was derived as the "abdominal fat area".

Figure 9 (menopausal model mouse, lower abdominal fat area), Figure 10 (menopausal model mouse, upper abdominal fat area), FIG. 11 (normal model mouse, lower abdominal fat area) and FIG. 12 (normal model mouse, upper abdominal fat area). 9 to 12, relative values are shown with the lower abdominal fat area or the upper abdominal fat area in the non-administered (CONT) group being set to 1.

As is clear from the comparison of FIGS. 9 and 10, administration of each of the BTS, DST, and BOT Kampo extracts was found to significantly reduce the lower abdominal fat area in the climacteric model mice. In addition, as is clear from the comparison of FIGS. 11 and 12, administration of each of the herbal extracts of BTS, DST, and BOT was found to significantly reduce the lower abdominal fat area even in normal model mice, but FIGS. As is clear from the comparison, the menopausal model mice showed a significant reduction effect on the lower abdominal fat area at a higher significance level.

Claims (5)

A lower abdominal fat reducing agent containing a Bofutsushosan extract, a Daisaikoto extract and/or a Boukito extract. The lower abdominal fat reducing agent according to claim 1, which is applied to post-menopausal women. 3. The agent for reducing abdominal fat according to claim 1 or 2, which is applied to women aged 55 and over. Applies to people with a ratio of lower to upper waist circumference of 1.1 or more,
The lower abdominal fat reducing agent according to any one of claims 1 to 3, wherein the upper abdominal circumference is the waist circumference at the navel level, and the lower abdominal circumference is the waist circumference at the position 50 mm below the navel level. The agent for reducing abdominal fat according to any one of claims 1 to 4, which is applied to persons with a lower abdominal circumference of 100 cm or more.

Images